{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:08:43Z","timestamp":1776276523416,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000142","name":"Arthritis Society","doi-asserted-by":"publisher","award":["SOG-22-192"],"award-info":[{"award-number":["SOG-22-192"]}],"id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05968-3","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T06:22:25Z","timestamp":1759126945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7053-559X","authenticated-orcid":false,"given":"Vienna","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-3347","authenticated-orcid":false,"given":"Neda","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5030-9135","authenticated-orcid":false,"given":"Vicki","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-4852","authenticated-orcid":false,"given":"Ursula","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-938X","authenticated-orcid":false,"given":"Jacquelyn J.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1656-0371","authenticated-orcid":false,"given":"Laurie","family":"Proulx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-6441","authenticated-orcid":false,"given":"Dwayne R.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2205-2683","authenticated-orcid":false,"given":"Mary A.","family":"De Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"5968_CR1","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/B978-0-444-52910-7.00047-7","volume":"112","author":"D Pohl","year":"2013","unstructured":"Pohl D, Benseler S (2013) Systemic inflammatory and autoimmune disorders. Handb Clin Neurol 112:1243\u20131252","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"5968_CR2","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/rheumatology\/keab544","volume":"61","author":"A Boel","year":"2022","unstructured":"Boel A, L\u00f3pez-Medina C, van der Heijde D, van Gaalen FA (2022) Age at onset in axial spondyloarthritis around the world: data from the assessment in spondyloarthritis international society peripheral involvement in spondyloarthritis study. Rheumatology (Oxford) 61(4):1468\u20131475","journal-title":"Rheumatology (Oxford)"},{"key":"5968_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1196\/annals.1351.019","volume":"1069","author":"TK Kvien","year":"2006","unstructured":"Kvien TK, Uhlig T, \u00d8deg\u00e5rd S, Heiberg MS (2006) Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 1069:212\u2013222","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"5968_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/14767058.2018.1498835","volume":"33","author":"H Aljary","year":"2020","unstructured":"Aljary H, Czuzoj-Shulman N, Spence AR, Abenhaim HA (2020) Pregnancy outcomes in women with rheumatoid arthritis: a retrospective population-based cohort study. J Matern Fetal Neonatal Med 33(4):618\u2013624","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"5","key":"5968_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/ecco-jcc\/jjaa225","volume":"15","author":"MA Kim","year":"2021","unstructured":"Kim MA, Kim YH, Chun J, Lee HS, Park SJ, Cheon JH et al (2021) The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 15(5):719\u2013732","journal-title":"J Crohns Colitis"},{"issue":"5","key":"5968_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/art.24462","volume":"61","author":"E Vinet","year":"2009","unstructured":"Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S (2009) Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 61(5):587\u2013592","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5968_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA (2011) Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 33(6):679\u2013707","journal-title":"Clin Ther"},{"issue":"4","key":"5968_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/09546634.2015.1054782","volume":"26","author":"PK Patel","year":"2015","unstructured":"Patel PK, King CR, Feldman SR (2015) Biologics and biosimilars. J Dermatolog Treat 26(4):299\u2013302","journal-title":"J Dermatolog Treat"},{"issue":"17","key":"5968_CR9","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s40265-018-1009-0","volume":"78","author":"BK Chen","year":"2018","unstructured":"Chen BK, Yang YT, Bennett CL (2018) Why biologics and biosimilars remain so expensive: despite two wins for biosimilars, the Supreme Court\u2019s recent rulings do not solve fundamental barriers to competition. Drugs 78(17):1777\u20131781","journal-title":"Drugs"},{"key":"5968_CR10","unstructured":"Canadian Institutes of Health Research. Prescribed Drug Spending in Canada. https:\/\/www.cihi.ca\/sites\/default\/files\/document\/pdex-report-2019-en-web.pdf."},{"key":"5968_CR11","unstructured":"08\/01\/2024 USFDAOfHCP. [Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/overview-health-care-professionals."},{"key":"5968_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102234","volume":"64","author":"CA Conran","year":"2022","unstructured":"Conran CA, Moreland LW (2022) A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol 64:102234","journal-title":"Curr Opin Pharmacol"},{"key":"5968_CR13","unstructured":"25 years of biologic therapy. Nature Reviews Rheumatology. https:\/\/www.nature.com\/collections\/ceabbcjjhf. November 10, 2023"},{"issue":"1","key":"5968_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3109\/00365520903362628","volume":"45","author":"Z Zelinkova","year":"2010","unstructured":"Zelinkova Z, Mensink PBF, Dees J, Kuipers EJ, van der Woude CJ (2010) Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol 45(1):46\u201350","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"5968_CR15","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","volume":"59","author":"NW Tsao","year":"2020","unstructured":"Tsao NW, Rebic N, Lynd LD, De Vera MA (2020) Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies. Rheumatology 59(8):1808\u20131817","journal-title":"Rheumatology"},{"key":"5968_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2016.11.004","volume":"76","author":"F Komaki","year":"2017","unstructured":"Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A (2017) Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-\u03b1 use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun 76:38\u201352","journal-title":"J Autoimmun"},{"issue":"1","key":"5968_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","volume":"20","author":"OH Nielsen","year":"2022","unstructured":"Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C (2022) Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 20(1):74-87.e3","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"5968_CR18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/1471-0528.17093","volume":"129","author":"LJ O'Byrne","year":"2022","unstructured":"O\u2019Byrne LJ, Alqatari SG, Maher GM, O\u2019Sullivan AM, Khashan AS, Murphy GP et al (2022) Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: a systematic review and meta-analysis. BJOG: Int J Obstet Gynaecol 129(8):1236\u20131246","journal-title":"BJOG: Int J Obstet Gynaecol"},{"key":"5968_CR19","unstructured":"Government of Canada Health Products and Food Branch. Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs. Revised Date 2016\/11\/14"},{"key":"5968_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.023","author":"L R\u00fcegg","year":"2025","unstructured":"R\u00fcegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO et al (2025) EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.02.023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5968_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/acr.24130","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD et al (2020) 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res 72(4):461\u2013488","journal-title":"Arthritis Care Res"},{"key":"5968_CR22","unstructured":"British Columbia. Biosimilars Initiative for health professionals. Last updated on November 6. [Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/programs\/biosimilars-initiative-health-professionals."},{"key":"5968_CR23","unstructured":"Kim J, Arias J, Gavura S (2024) National and International Policies on the Use of Biosimilars: An Environmental Scan. [Available from: https:\/\/canjhealthtechnol.ca\/index.php\/cjht\/article\/download\/PR0006\/2015?inline=1%26utm."},{"issue":"11","key":"5968_CR24","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/ajg.2016.405","volume":"111","author":"MD Larsen","year":"2016","unstructured":"Larsen MD, Friedman S, Magnussen B, N\u00f8rg\u00e5rd BM (2016) Birth outcomes in children fathered by men treated with anti-TNF-\u03b1 agents before conception. Am J Gastroenterol 111(11):1608\u20131613","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"5968_CR25","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1093\/rheumatology\/keab910","volume":"61","author":"LF Perez-Garcia","year":"2022","unstructured":"Perez-Garcia LF, R\u00f6der E, Smeele HTW, Goekoop R, Hazes JMW, Kok MR et al (2022) Paternal inflammatory arthritis is associated with a higher risk of miscarriage: results of a large multicentre study (iFAME-Fertility). Rheumatology (Oxford) 61(8):3390\u20133395","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5968_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8(1):19\u201332","journal-title":"Int J Soc Res Methodol"},{"issue":"7","key":"5968_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467\u2013473","journal-title":"Ann Intern Med"},{"key":"5968_CR28","unstructured":"Institute TJB. Joanna Briggs Institute Reviewers\u2019 Manual 2015: Methodology for JBI Scoping Reviews2015."},{"key":"5968_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25502","author":"V Cheng","year":"2025","unstructured":"Cheng V, Amiri N, Cheng V, Ellis U, Cragg JJ, Harrison M et al (2025) Pregnancy outcomes of targeted synthetic disease-modifying antirheumatic drugs among patients with autoimmune diseases: a scoping review. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.25502","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"5968_CR30","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/ibd\/izac111","volume":"28","author":"A Kawamoto","year":"2022","unstructured":"Kawamoto A, Fujii T, Mitani R, Suzuki Y, Yauchi T, Okamoto R (2022) Serum levels of infliximab biosimilar in a child delivered from a mother treated for ulcerative colitis. Inflamm Bowel Dis 28(8):1298\u20131299","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"5968_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/reprodmed6010006","volume":"6","author":"G Fontana","year":"2025","unstructured":"Fontana G, Fredi M, Nalli C, Orabona R, Guaragni B, Picciau L et al (2025) Management of Evans\u2019 syndrome in pregnancy: a case report and a narrative review. Reprod Med 6(1):6","journal-title":"Reprod Med"},{"issue":"2","key":"5968_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae044","volume":"8","author":"AT Ch\u00edcharo","year":"2024","unstructured":"Ch\u00edcharo AT, Lopes AR, Barreira S, Pinto L, Cruz-Machado AR, Capela S (2024) Maternal and perinatal outcomes in pregnant women with rheumatic diseases treated with biosimilar TNF inhibitors. Rheumatol Adv Pract 8(2):rkae044","journal-title":"Rheumatol Adv Pract"},{"issue":"supplement_1","key":"5968_CR33","doi-asserted-by":"publisher","first-page":"S419","DOI":"10.1093\/ecco-jcc\/jjx180.741","volume":"12","author":"M Kolar","year":"2018","unstructured":"Kolar M, Duricova D, Bortlik M, Lukas M, Hruba V, Machkova N et al (2018) P614 pregnancy outcomes in women with IBD treated with biosimilar infliximab. J Crohns Colitis 12(supplement_1):S419\u2013S420","journal-title":"J Crohns Colitis"},{"issue":"3","key":"5968_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40259-014-0094-1","volume":"28","author":"K McKeage","year":"2014","unstructured":"McKeage K (2014) A review of CT-P13: an infliximab biosimilar. BioDrugs 28(3):313\u2013321","journal-title":"BioDrugs"},{"key":"5968_CR35","unstructured":"U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process%26ApplNo=125544"},{"issue":"2","key":"5968_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1753495X211028779","volume":"15","author":"R Scott","year":"2022","unstructured":"Scott R, Parker H, McCartney S, Harrow P, Williams D, Giles I (2022) Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancy. Obstet Med 15(2):104\u2013107","journal-title":"Obstet Med"},{"key":"5968_CR37","doi-asserted-by":"publisher","unstructured":"Long MD, Kane S, Beaulieu D, Abraham B, Zhang X, Mahadevan U. Use of Biosimilars to Infliximab During Pregnancy in Women With Inflammatory Bowel Disease: Results From the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Study. Clin Transl Gastroenterol. 2024;15(12):e00795. https:\/\/doi.org\/10.14309\/ctg.0000000000000795","DOI":"10.14309\/ctg.0000000000000795"},{"key":"5968_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/271363","volume":"2008","author":"DT Klink","year":"2008","unstructured":"Klink DT, van Elburg RM, Schreurs MW, van Well GT (2008) Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008:271363","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"5968_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4049\/immunohorizons.1700057","volume":"2","author":"GG Fouda","year":"2018","unstructured":"Fouda GG, Martinez DR, Swamy GK, Permar SR (2018) The impact of IgG transplacental transfer on early life immunity. Immunohorizons 2(1):14\u201325","journal-title":"Immunohorizons"},{"issue":"7","key":"5968_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/acr.23434","volume":"70","author":"NW Tsao","year":"2018","unstructured":"Tsao NW, Lynd LD, Sadatsafavi M, Hanley G, De Vera MA (2018) Patterns of biologics utilization and discontinuation before and during pregnancy in women with autoimmune diseases: a population-based cohort study. Arthritis Care Res (Hoboken) 70(7):979\u2013986","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5968_CR41","unstructured":"Government of Canada. Biosimilars in Canada: Policies to Promote Switching and What It Means for Payers. Presentation to the 2023 Annual CAHSPR Conference. May\/June 2023. [Available from: https:\/\/www.canada.ca\/en\/patented-medicine-prices-review\/services\/npduis\/analytical-studies\/posters\/biosimilars-policies-promote-switching.html."},{"issue":"2","key":"5968_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1753495X20948984","volume":"14","author":"K Giannakou","year":"2021","unstructured":"Giannakou K (2021) Perinatal epidemiology: issues, challenges, and potential solutions. Obstet Med 14(2):77\u201382","journal-title":"Obstet Med"},{"issue":"10","key":"5968_CR43","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the planetra study. Ann Rheum Dis 72(10):1613\u20131620","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5968_CR44","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I (2020) The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther 108(4):734\u2013755","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"5968_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","volume":"34","author":"V Strand","year":"2020","unstructured":"Strand V, Gon\u00e7alves J, Hickling TP, Jones HE, Marshall L, Isaacs JD (2020) Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs 34(1):27\u201337","journal-title":"BioDrugs"},{"issue":"11","key":"5968_CR46","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1111\/bcp.14330","volume":"86","author":"J Kang","year":"2020","unstructured":"Kang J, Eudy-Byrne RJ, Mondick J, Knebel W, Jayadeva G, Liesenfeld K-H (2020) Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. Br J Clin Pharmacol 86(11):2274\u20132285","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"5968_CR47","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","volume":"72","author":"T D\u00f6rner","year":"2013","unstructured":"D\u00f6rner T, Strand V, Casta\u00f1eda-Hern\u00e1ndez G, Ferraccioli G, Isaacs JD, Kvien TK et al (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72(3):322\u2013328","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5968_CR48","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/cpt.3033","volume":"114","author":"C-A Cheng","year":"2023","unstructured":"Cheng C-A, Jiang A-L, Liu Y-R, Chang L-C (2023) Investigation of immunogenicity assessment of biosimilar monoclonal antibodies in the United States. Clin Pharmacol Ther 114(6):1274\u20131284","journal-title":"Clin Pharmacol Ther"},{"key":"5968_CR49","unstructured":"U.S. Food & Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. April 2015. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product"},{"issue":"7","key":"5968_CR50","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00384-022-04185-9","volume":"37","author":"ZI Tarar","year":"2022","unstructured":"Tarar ZI, Farooq U, Zafar MU, Saleem S, Nawaz A, Kamal F et al (2022) A national study of pregnancy-related maternal and fetal outcomes in women with inflammatory bowel disease. Int J Colorectal Dis 37(7):1535\u20131543","journal-title":"Int J Colorectal Dis"},{"key":"5968_CR51","doi-asserted-by":"publisher","unstructured":"Cheng V, Amiri N, Cheng V, Ellis U, Cragg JJ, Proulx L, et al. Pregnancy outcomes of non-tumour necrosis factor inhibitor biologic disease-modifying antirheumatic drugs among individuals with autoimmune diseases: a scoping review and proposed framework for reporting outcomes. EULAR Rheumatology Open. 2025;1(3):182-202. https:\/\/doi.org\/10.1016\/j.ero.2025.06.011","DOI":"10.1016\/j.ero.2025.06.011"},{"issue":"2","key":"5968_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-0035-1556745","volume":"4","author":"S Alwan","year":"2015","unstructured":"Alwan S, Chambers CD (2015) Identifying human teratogens: an update. J Pediatr Genet 4(2):39\u201341","journal-title":"J Pediatr Genet"},{"key":"5968_CR53","unstructured":"U.S. Department of health and human services. Food and drug administration. Nonproprietary naming of biological products guidance for industry. January 2017."},{"key":"5968_CR54","unstructured":"Klinginsmith M, Winters R, Goldman J. Laryngomalacia. [Updated 2024 Jan 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-23. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544266\/."},{"issue":"2","key":"5968_CR55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/OGX.0000000000000405","volume":"72","author":"BS Harris","year":"2017","unstructured":"Harris BS, Bishop KC, Kemeny HR, Walker JS, Rhee E, Kuller JA (2017) Risk factors for birth defects. Obstet Gynecol Surv 72(2):123\u2013135","journal-title":"Obstet Gynecol Surv"},{"key":"5968_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.842878","author":"S Zhang","year":"2022","unstructured":"Zhang S, Qiu X, Wang T, Chen L, Li J, Diao J et al (2022) Hypertensive disorders in pregnancy are associated with congenital heart defects in offspring: a systematic review and meta-analysis. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2022.842878","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"5968_CR57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12884-016-0987-8","volume":"16","author":"S Bellizzi","year":"2016","unstructured":"Bellizzi S, Ali MM, Abalos E, Betran AP, Kapila J, Pileggi-Castro C et al (2016) Are hypertensive disorders in pregnancy associated with congenital malformations in offspring? Evidence from the WHO multicountry cross sectional survey on maternal and newborn health. BMC Pregnancy Childbirth 16(1):198","journal-title":"BMC Pregnancy Childbirth"},{"key":"5968_CR58","doi-asserted-by":"publisher","unstructured":"Cheng, V., Kang, P., Proulx, L. et al. Lessons learned from Caf\u00e9 Scientifique public webinars on pregnancy and parenting in arthritis: perspectives from patients, clinicians, and researchers. BMC Proc 19 (Suppl 7), 10 (2025). https:\/\/doi.org\/10.1186\/s12919-025-00323-7 https:\/\/doi.org\/10.1186\/s12919-025-00323-7","DOI":"10.1186\/s12919-025-00323-7"},{"issue":"2","key":"5968_CR59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00296-023-05398-z","volume":"44","author":"A Gupta","year":"2024","unstructured":"Gupta A, De Vera MA, Rebi\u0107 N, Amiri N (2024) Pre-pregnancy planning for female patients seen at a pregnancy and rheumatic diseases clinic: a retrospective analysis of patients with rheumatic diseases seeking pregnancy-related care. Rheumatol Int 44(2):283\u2013289","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05968-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05968-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05968-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:02:47Z","timestamp":1761588167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05968-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["5968"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05968-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not Applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"241"}}